pharma news today glp-1 2025 A biopharmaceutical company is looking for ways to slim down household pets. Okava Pharmaceuticals, a San Francisco based company, is introducing a new clinical weight loss study for cats. MEOW-1, as Tirzepatide | Radio Compass Blog

PHGG or acacia fiber in small doses (3 to 5 grams) mixed into liquid can provide benefits without significant stomach volume

Lancet Gastroenterol Hepatol 9:957964 Feighery AM, Oblizajek NR, Vogt MNP, Bi D, League J 3rd, Buttar NS, Prichard DO (2023) Retained food during esophagogastroduodenoscopy is a risk factor for gastric-to-pulmonary aspiration

For instance, In July 2024, the MHRA approved Semaglutide, a GLP-1 receptor agonist, to reduce the risk of major cardiovascular events in obese or overweight people, underscoring its expanding benefits beyond glycemic control In December 2023, Eli Lilly and Company launched Zepbound (tirzepatide), the first dual GIP/GLP-1 receptor agonist for chronic weight management in adults with obesity or other weight-related medical problems such as hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea or cardiovascular disease Together, such developments are reshaping the role of GLP-1 analogues from single-purpose treatments to comprehensive metabolic health solutions

And by decreasing the chronic inflammation that's happening in our skin, you can really augment the skin from the outside in

Descriptive data are presented in Table 1